NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD
NVAX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. NVAX has a medium profitability rating, but doesn't score so well on its financial health evaluation. NVAX is not valued too expensively and it also shows a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 37.02% | ||
ROE | N/A | ||
ROIC | 38.36% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 33.69% | ||
PM (TTM) | 38.14% | ||
GM | 87.52% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -1.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.06 | ||
Quick Ratio | 2.03 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 3.13 | ||
Fwd PE | 18.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 0.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
7.29
+0.18 (+2.53%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 3.13 | ||
Fwd PE | 18.97 | ||
P/S | 0.94 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | 0.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 37.02% | ||
ROE | N/A | ||
ROCE | 48.55% | ||
ROIC | 38.36% | ||
ROICexc | 239.72% | ||
ROICexgc | 1222.82% | ||
OM | 33.69% | ||
PM (TTM) | 38.14% | ||
GM | 87.52% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0.48 | ||
Cap/Depr | 16.56% | ||
Cap/Sales | 0.59% | ||
Interest Coverage | 22.06 | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.06 | ||
Quick Ratio | 2.03 | ||
Altman-Z | -1.89 |